MedTrace Logo

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

NCT03467984 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2019-08-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immunogenicity of LBVE (Multivalent Pneumococcal Conjugate Vaccine) in healthy infants.

Conditions

  • Pneumococcal Infection

Interventions

BIOLOGICAL

LBVE

Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

BIOLOGICAL

Prevnar13

13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Weeks
Max Age
8 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-25
Primary Completion
2018-10-05
Completion
2019-03-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467984 on ClinicalTrials.gov